ID   CLF_PEDS0005_T2B
AC   CVCL_C9B5
SY   CLF_PEDS0005_T2b
DR   BioGRID_ORCS_Cell_line; 1224
DR   dbGAP; phs001800.v1.p1
DR   GEO; GSM3039704
DR   Wikidata; Q123030938
RX   PubMed=30860482;
CC   Population: African American.
CC   Sequence variation: Gene deletion; HGNC; HGNC:11103; SMARCB1; Zygosity=Heterozygous (from autologous cell line CLF_PEDS0005_T1).
CC   Sequence variation: Gene fusion; HGNC; HGNC:28667; C1orf116 + HGNC; HGNC:11103; SMARCB1; Name(s)=SMARCB1-C1orf116; Note=SMARCB1 intron 1 fused to C1orf116 C-terminal (from autologous cell line CLF_PEDS0005_T1).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; CRISPR screening.
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C7572; Kidney medullary carcinoma
DI   ORDO; Orphanet_319319; Renal medullary carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C9B2 ! CLF_PEDS0005_N
OI   CVCL_C9B3 ! CLF_PEDS0005_T1
OI   CVCL_C9B4 ! CLF_PEDS0005_T2A
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 10-04-25; Version: 4
//
RX   PubMed=30860482; DOI=10.7554/eLife.44161; PMCID=PMC6436895;
RA   Hong A.L., Tseng Y.-Y., Wala J.A., Kim W.-J., Kynnap B.D., Doshi M.B.,
RA   Kugener G., Sandoval G.J., Howard T.P., Li J., Yang X.-P., Tillgren M.,
RA   Ghandi M., Sayeed A., Deasy R., Ward A., McSteen B., Labella K.M.,
RA   Keskula P., Tracy A., Connor C., Clinton C.M., Church A.J.,
RA   Crompton B.D., Janeway K.A., Van Hare B., Sandak D., Gjoerup O.V.,
RA   Bandopadhayay P., Clemons P.A., Schreiber S.L., Root D.E.,
RA   Gokhale P.C., Chi S.N., Mullen E.A., Roberts C.W.M., Kadoch C.,
RA   Beroukhim R., Ligon K.L., Boehm J.S., Hahn W.C.;
RT   "Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive
RT   to proteasome inhibition.";
RL   eLife 8:e44161.1-e44161.32(2019).
//